Medical Device Registration Timelines: Indonesia, Saudi Arabia & Brazil

Among our most-asked questions, this is the hardest to answer in one sentence. The answer depends on three things: the product's risk class, whether the documents are complete, how reliable the local representative is.

Worse, many guides online are outdated. The typical case is Saudi Arabia — some sources still cite "low-risk products via MDL fast registration, getting a number in 1–4 weeks", but this route was discontinued in 2022.

In this article, we break down the current registration pathways in Indonesia, Saudi Arabia and Brazil: risk classes, procedures, required documents, actual timelines and where the money goes.

Before going country by country, three requirements apply across all three markets. Settle them first to save a lot of repetitive work later.

1. Local representative is mandatory and holds the certificate

None of the three countries accepts direct applications from overseas manufacturers. Indonesia requires a local license holder (with IDAK + CDAKB qualifications), Saudi Arabia requires a local Authorized Representative (AR), and Brazil requires a Brazilian Registration Holder (BRH).

The key is not "whether to find one", but under whose name the registration number is held. In all three markets, the certificate belongs to the local representative; changing representatives means transferring the registration, which is heavy work and the most dispute-prone part later.

2. ISO 13485 is a prerequisite, not a bonus

All three markets treat ISO 13485 as the basic entry threshold. Brazil goes further: Class III and IV products also require factory BGMP certification.

3. Language localization is mandatory

Indonesian (labels + IFU, certified local translation), Arabic (Saudi, or Arabic/English bilingual), Portuguese (Brazil, all submitted documents). Translation is not a final step but part of the schedule — many projects get stuck on translation and notarization.

What to prepare

Core document checklist

• ISO 13485 certificate
• Certificate of Free Sale (CFS) — notarized + legalized
• Technical file (per ASEAN CSDT template)
• Risk management file (ISO 14971)
• Active devices: IEC 60601 electrical safety + EMC reports
• Body-contacting materials: ISO 10993 biocompatibility
• Clinical Evaluation Report (CER): Class A via predicate literature; C/D require clinical data
• Indonesian labels & IFU

Timeline

Official fee (PNBP): Class A ~IDR 1.5M (~USD 95) · B/C ~IDR 3M (~USD 225) · D ~IDR 5M (~USD 350).

Three easy-to-miss deadlines

One misconception to correct first

Many guides still mention Saudi's "two pathways": low-risk via MDL listing (1–4 weeks), medium-high risk via MDMA.

Since January 2022, MDMA2 (full technical file application) is the only pathway. All devices, regardless of risk class, must submit a full technical file and designate a local Authorized Representative.

In other words: having CE does not mean fast clearance, but the classification conclusion and technical file behind CE can still be reused.

What to prepare

Product registration MDMA · Document checklist

• ISO 13485 certificate
• Certificate of Free Sale
• Declaration of Conformity
• Essential Principles checklist
• Risk management file (ISO 14971)
• Biocompatibility, electrical safety, EMC (IEC 60601 series)
• Software lifecycle documentation (IEC 62304) + cybersecurity (if applicable)
• Sterilization and shelf-life validation (sterile products)
• Clinical Evaluation Report (CER)
• Arabic labels & IFU (or Arabic/English bilingual)
• UDI compliance

Timeline

Validity: MDMA certificate is usually 3 years, renewable. Sources differ between 3 and 5 years; confirm with the latest SFDA announcement.

Official fees: classification ~SAR 1,000; MDMA by class ~SAR 2,000–3,000 (A), 6,000–10,000 (B), 12,000–15,000 (C), 15,000–20,000 (D), varying by source.

Brazil's key feature is two pathways with vastly different difficulty levels.

Pathway 1: Cadastro / Notificação (Class I, II)

Pathway 2: Registro (Class III, IV)

What to prepare

• Full Portuguese documentation (technical file, LOA, labels, IFU)
• BRH designation documents
• Risk analysis (ISO 14971)
• Clinical evidence (Class III/IV)
• GMP certificate (BGMP or MDSAP)

Cost overview

Official review time in all three countries is far shorter than the actual project cycle. What really takes time is completing the CSDT file, risk management, clinical evaluation, biocompatibility and electrical safety — especially items not done domestically and needing to start from scratch.

Indonesia's CFS and LOA require Chinese notarization + consular legalization at the embassy, taking weeks in total. These steps cannot be expedited; start them early.

This is not a purchasing decision but a structural decision. An importer-type representative may bring channels, at the cost of the certificate being under their name and limited distributor switching later; an independent third-party preserves commercial flexibility but brings no customers; a self-built local entity offers the strongest control but the highest barrier and cost.

Many makers treat registration as a "certificate" errand and only start when orders come, only to find the cycle longer than the lead time.

A more practical approach is to treat it as a scheduling problem: first confirm the product's risk class in each market (the same product may be classified differently across countries; do not assume), then work backwards on document preparation, notarization, review and deficiency rounds to decide whether and when to enter.

There is also a strategic consensus: secure approval in a developed market (CE or FDA) first, then expand to emerging markets, usually more cost-effective than starting from scratch market by market. Although Saudi cancelled the GHTF-reliant pathway, the classification conclusion, technical file, and clinical data behind existing approvals can still be reused across countries.

If you are evaluating a market's registration pathway or want to understand compliance requirements in a target country, feel free to message us directly. MedWish will provide public, general market information based on your product and target markets.